<DOC>
	<DOCNO>NCT01282151</DOCNO>
	<brief_summary>This study : - A multicenter , prospective , randomize , phase 3 trial . - To prove non-inferiority Taxotere/Cisplatin compare Pemetrexed/Cisplatin front line treatment patient non-squamous cell lung cancer . - 276 patient recruit .</brief_summary>
	<brief_title>TaxoteRe Plus Cisplatin Versus AlImta Plus Cisplatin 1st Line Non-squamous Cell Type Lung Cancer</brief_title>
	<detailed_description>Docetaxel use 60mg/m2 3 weekly dosage Japan several east Asian institution . Docetaxel 60mg/m2 Cisplatin 70 mg/m3 3 weekly regimen compare Pemetrexed 500mg/m2 Cisplatin 70 mg/m2 3 weekly regimen first line NSCLC non-squamous histology .</detailed_description>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>Age &gt; = 18 year old ECOG performance status 02 Nonsquamous cell type nonsmall cell lung cancer ( NSCLC ) Stage IV , Stage IIIB treat curative intent Relapsed surgery radiation therapy No prior chemotherapy except adjuvant chemotherapy concurrent chemoradiation treatment . The last dose adjuvant chemotherapy least 6 month early randomization , regimen contain docetaxel pemetrexed . No prior immunotherapy , biologic therapy Measurable lesion Response Evaluation Criteria Solid Tumors ( RECIST ) version 1.1 Hemoglobin &gt; =9.0g/dl , Platelet &gt; =100,000/uL , neutrophil &gt; =1,500 /uL Creatinine &lt; =1.5 x upper normal limit creatinine clearance &gt; =60 mL/min Bilirubin &lt; =1.5 x upper normal limit , Transaminases &lt; =2 x upper normal limit Alkaline phosphatase &lt; =2 x upper normal limit Written inform consent Pregnancy , Lactating woman Woman child bear age refuse pregnancy test Moderate great grade 1 motor sensory neurotoxicity Hypersensitivity taxane Comorbidity poor medical condition Other malignancy ( except cure basal cell carcinoma uterine cervical carcinoma situ ) Concurrent treatment investigational drug within 30 day randomization Active treatment anticancer chemotherapy EGFR mutation ( exon 19 deletion , L858R , L861Q , G719A/C/S )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>NSCLC</keyword>
	<keyword>Non Squamous cell</keyword>
	<keyword>Docetaxel</keyword>
	<keyword>Pemetrexed</keyword>
</DOC>